Themis Bioscience GmbH, of Vienna, licensed worldwide rights to an oncolytic measles virus platform from Max-Planck-Innovation GmbH, of Munich. The platform was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Terms of the deal weren't disclosed.